Wei Guo

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

Ana Oaknin, Anna V. Tinker, Lucy Gilbert et al. · JAMA Oncology · 2020 · 357 citations · Full text

Medicine, Oncology, Pharmacology +16

Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library

Dik‐Lung Ma, Daniel Shiu‐Hin Chan, Wei Guo et al. · Chemical Communications · 2014 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

In vivo immune interactions of multipotent stromal cells underlie their long-lasting pain-relieving effect

Wei Guo, Satoshi Imai, Jiale Yang et al. · Scientific Reports · 2017 · 43 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer

Ana Oaknin, Linda Duska, Ryan J. Sullivan et al. · Gynecologic Oncology · 2019 · 43 citations

Medicine, Oncology, Pharmacology +14

Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors

Xiaohan Song, Pu Sun, Jiang Wang et al. · European Journal of Medicinal Chemistry · 2020 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14